Log in or Sign up for Free to view tailored content for your specialty!
Neurocritical Care News
Intra-molecular compound advanced as potential disease-modifying therapy for ALS
A Cincinnati-based life sciences company announced that one of its development candidates, ASHA-624, will be advanced as a potential disease modifying therapy for amyotrophic lateral sclerosis.
Point-of-care brain wave monitoring can help improve concussion care
Despite the brain being one of the most important organs of the body, breakthroughs in brain health, specifically the way we measure cognition, have been largely unchanged in decades.
Log in or Sign up for Free to view tailored content for your specialty!
First-in-human clinical trial for disease-modifying Parkinson’s treatment commences
A United Kingdom-based clinical-stage biotech company has announced commencement of a first-in-human clinical trial of a selective central nervous system-penetrant compound to treat Parkinson’s disease.
FDA grants clearance to TMS device for MDD in young people
The FDA has granted clearance to a transcranial magnetic stimulation device as an adjunctive treatment for major depressive disorder in patients aged 15 to 21 years, according to the manufacturer.
Multiple Sclerosis Awareness Month: Latest research, treatments from ACTRIMS 2024
March is Multiple Sclerosis Awareness Month, a time to improve knowledge of and highlight the growing treatment options for progressive types of this degenerative disease.
Interim trial results show THC-based treatment reduces agitation in Alzheimer’s disease
IGC Pharma has announced positive interim results from an ongoing phase 2 trial investigating IGC-AD1, a natural THC-based oral formulation, as a treatment for agitation in dementia from Alzheimer’s disease.
Partnership aims to commercialize brain-computer interface technology
A Boston-area developer of brain-computer interface technology and a Canadian biotech firm have announced a collaboration to globally commercialize the former’s brain health tools.
‘Havana syndrome’ not correlated with results of MRI-based biomarkers, neuropsych tests
Two separate studies found no evidence to link anomalous health incidents with MRI-based biomarkers of disease or adverse results of neuropsychological testing among U.S. government staff, their families and matched controls.
Bristol Myers acquires Karuna, including novel muscarinic neuropsychiatric drug
Bristol Myers Squibb has completed its acquisition of Karuna Therapeutics, including Karuna’s therapeutic portfolio featuring a novel, investigational muscarinic antipsychotic to treat schizophrenia and Alzheimer’s disease.
Link between psychedelic use, manic symptoms in teens may be associated with genetics
While psychedelic use may be associated with fewer psychotic symptoms among adolescents, the link between psychedelics and manic symptoms appears to be associated with genetic vulnerability to schizophrenia or bipolar disorder, data show.
-
Headline News
Rise in alcohol use during pandemic endures as 'an alarming public health issue'
November 14, 20242 min read -
Headline News
AI identified patient messages sent by proxies, but also broke confidentiality
November 14, 20242 min read -
Headline News
Diabetes inequities persist worldwide, especially for low-, middle-income countries
November 14, 20243 min read
-
Headline News
Rise in alcohol use during pandemic endures as 'an alarming public health issue'
November 14, 20242 min read -
Headline News
AI identified patient messages sent by proxies, but also broke confidentiality
November 14, 20242 min read -
Headline News
Diabetes inequities persist worldwide, especially for low-, middle-income countries
November 14, 20243 min read